肝细胞癌中细胞因子信号传导抑制因子1与调节性T淋巴细胞/辅助性T淋巴细胞17平衡的关系

宋瑞; 李静; 杨红菊; 李敏玥; 游晶

doi:10.3969/j.issn.1001-5256.2022.11.038

肝细胞癌中细胞因子信号传导抑制因子1与调节性T淋巴细胞/辅助性T淋巴细胞17平衡的关系

DOI: 10.3969/j.issn.1001-5256.2022.11.038

宋瑞¹,
李静²,
杨红菊¹,
李敏玥¹,
游晶^1, , ,

1.
国家卫健委毒品依赖和戒治重点实验室，昆明医科大学第一附属医院老年消化内科，昆明 650032
2.
昆明医科大学公共卫生学院，昆明 650500

基金项目:

国家自然科学基金 (81760111);

国家自然科学基金 (81760617);

国家卫生健康委员会毒品依赖和戒治重点实验室科学研究A类重点项目 (2020DAMARA-003)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：宋瑞负责文献阅读及综述撰写；李静、杨红菊、李敏玥负责提供意见；游晶负责课题设计，拟定写作思路，指导撰写、修改文章并最后定稿。

详细信息

通信作者:
游晶，jingyoukm@126.com

计量
- 文章访问数: 663
- HTML全文浏览量: 216
- PDF下载量: 38
- 被引次数: 0
出版历程
- 收稿日期: 2022-03-13
- 录用日期: 2022-05-26
- 出版日期: 2022-11-20

Role of signal transducer and activator of transcription 1 in regulation of Treg/Th17 balance in hepatocellular carcinoma

Rui SONG¹,
Jing LI²,
Hongju YANG¹,
Minyue LI¹,
Jing YOU^{1
, ,
,}

1.
The NHC Key Laboratory of Drug Addiction Medicine, Department of Geriatric Gastroenterology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China
2.
School of Public Health, Kunming Medical University, Kunming 650500, China

Research funding:

National Natural Science Foundation of China (81760111);

National Natural Science Foundation of China (81760617);

The NHC Key Laboratory of Drug Addiction Medicine Science Research A Key Project (2020DAMARA-003)

More Information

Corresponding author: YOU Jing, jingyoukm@126.com(ORCID: 0000-0002-5919-5864)

摘要

摘要: 调节性T淋巴细胞(Treg)和辅助性T淋巴细胞17(Th17)在肝细胞癌(HCC)的肿瘤微环境中发挥重要作用，Treg/Th17失衡与HCC的侵袭和进展密切相关。同时，细胞因子信号传导抑制因子1(SOCS1)作为Janus激酶/信号转导和转录激活因子信号通路的负调控因子之一，参与调控Treg细胞和Th17细胞的增殖、分化。本文主要分析HCC中SOCS1与Treg/Th17平衡的关系，探究HCC发生发展过程中的免疫相关机制。
- 癌，肝细胞 /
- 细胞因子类 /
- 信号传导 /
- T淋巴细胞，调节性 /
- T淋巴细胞，辅助诱导
Abstract: The regulatory T cells (Treg) and helper T cells 17 (Th17) play an important role in regulation of the tumor microenvironment in hepatocellular carcinoma (HCC) because Treg/Th17 imbalance was associated with HCC cell invasion and progression. Moreover, the suppressor of cytokine signaling 1 (SOCS1), a negative regulator of the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway, regulates Treg and Th17 proliferation and differentiation. This review summarized and discussed the recent advancement and progress in control of the Treg/Th17 balance in HCC and the immunity-related mechanisms in HCC development and progression, i.e., the SOCS1 structure and functions, SOCS1 role in regulation of Treg/Th17 balance in HCC, and future research direction of the field.
- Carcinoma, Hepatocellular /
- Cytokines /
- Signal Transduction /
- T-Lymphocytes, Regulatory /
- T-Lymphocytes, Helper-Inducer

HTML全文

图 1 在HCC中SOCS1与Treg/Th17平衡的关系

Figure 1. The relationship between SOCS1 and Treg/Th17 balance in HCC

下载: 全尺寸图片幻灯片

图 2 SOCS1通过调控Foxp3的表达维持Treg功能的稳定^[20]

注：“→”表示促进，“ ”表示抑制。

Figure 2. SOCS1 maintains the stability of Treg function by regulating Foxp3 expression^[20]

下载: 全尺寸图片幻灯片

参考文献(48)

[1]	General Office of National Health Commission. Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 1-16. DOI: 10.3969/j.issn.1001-5256.2022.02. 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 1-16. DOI: 10.3969/j.issn.1001-5256.2022.02.
[2]	LU C, RONG D, ZHANG B, et al. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities[J]. Mol Cancer, 2019, 18(1): 130. DOI: 10.1186/s12943-019-1047-6.
[3]	LIU LX, CAI W. Current situation and prospect of immunotherapy for hepatocellular carcinoma[J]. Chin J Dig Surg, 2020, 19(2): 119-122. DOI: 10.3760/cma.j.issn.1673-9752.2020.02.002. 刘连新, 蔡伟. 肝细胞癌免疫治疗的现状和展望[J]. 中华消化外科杂志, 2020, 19(2): 119-122. DOI: 10.3760/cma.j.issn.1673-9752.2020.02.002.
[4]	BIAN J, LIN J, LONG J, et al. T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy[J]. Am J Cancer Res, 2020, 10(12): 4585-4606.
[5]	ZHANG W, LIU X, ZHU Y, et al. Transcriptional and posttranslational regulation of Th17/Treg balance in health and disease[J]. Eur J Immunol, 2021, 51(9): 2137-2150. DOI: 10.1002/eji.202048794.
[6]	CHO HJ, CHEONG JY. Role of immune cells in patients with hepatitis B virus-related hepatocellular carcinoma[J]. Int J Mol Sci, 2021, 22(15): 8011. DOI: 10.3390/ijms22158011.
[7]	XIE J, WANG M, CHENG A, et al. The role of SOCS proteins in the development of virus-induced hepatocellular carcinoma[J]. Virol J, 2021, 18(1): 74. DOI: 10.1186/s12985-021-01544-w.
[8]	SHARMA J, LARKIN J 3rd. Therapeutic implication of SOCS1 modulation in the treatment of autoimmunity and cancer[J]. Front Pharmacol, 2019, 10: 324. DOI: 10.3389/fphar.2019.00324.
[9]	YOSHIMURA A, ITO M, MISE-OMATA S, et al. SOCS: negative regulators of cytokine signaling for immune tolerance[J]. Int Immunol, 2021, 33(12): 711-716. DOI: 10.1093/intimm/dxab055.
[10]	LIAU N, LAKTYUSHIN A, LUCET IS, et al. The molecular basis of JAK/STAT inhibition by SOCS1[J]. Nat Commun, 2018, 9(1): 1558. DOI: 10.1038/s41467-018-04013-1.
[11]	SHARMA J, COLLINS TD, ROACH T, et al. Suppressor of cytokine signaling-1 mimetic peptides attenuate lymphocyte activation in the MRL/lpr mouse autoimmune model[J]. Sci Rep, 2021, 11(1): 6354. DOI: 10.1038/s41598-021-86017-4.
[12]	CHEN H, WU Y, LI K, et al. Optimization of phosphotyrosine peptides that target the SH2 domain of SOCS1 and block substrate ubiquitination[J]. ACS Chem Biol, 2022, 17(2): 449-462. DOI: 10.1021/acschembio.1c00884.
[13]	SEIF F, KHOSHMIRSAFA M, AAZAMI H, et al. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells[J]. Cell Commun Signal, 2017, 15(1): 23. DOI: 10.1186/s12964-017-0177-y.
[14]	IIZUKA-KOGA M, NAKATSUKASA H, ITO M, et al. Induction and maintenance of regulatory T cells by transcription factors and epigenetic modifications[J]. J Autoimmun, 2017, 83: 113-121. DOI: 10.1016/j.jaut.2017.07.002.
[15]	NI X, WANG Q, GU J, et al. Clinical and basic research progress on Treg-induced immune tolerance in liver transplantation[J]. Front Immunol, 2021, 12: 535012. DOI: 10.3389/fimmu.2021.535012.
[16]	ILANGUMARAN S, BOBBALA D, RAMANATHAN S. SOCS1: Regulator of T cells in autoimmunity and cancer[J]. Curr Top Microbiol Immunol, 2017, 410: 159-189. DOI: 10.1007/82_2017_63.
[17]	TAKAHASHI R, NAKATSUKASA H, SHIOZAWA S, et al. SOCS1 is a key molecule that prevents regulatory T cell plasticity under inflammatory conditions[J]. J Immunol, 2017, 199(1): 149-158. DOI: 10.4049/jimmunol.1600441.
[18]	RAMSDELL F, ZIEGLER SF. FOXP3 and scurfy: how it all began[J]. Nat Rev Immunol, 2014, 14(5): 343-349. DOI: 10.1038/nri3650.
[19]	SOBAH ML, LIONGUE C, WARD AC. SOCS proteins in immunity, inflammatory diseases, and immune-related cancer[J]. Front Med (Lausanne), 2021, 8: 727987. DOI: 10.3389/fmed.2021.727987.
[20]	YOSHIMURA A, SUZUKI M, SAKAGUCHI R, et al. SOCS, inflammation, and autoimmunity[J]. Front Immunol, 2012, 3: 20. DOI: 10.3389/fimmu.2012.00020.
[21]	WANG WZ, XIANG XX. Immunological mechanism of Treg/Th17 and Th1/Th2 balance in autoimmune hepatitis and new targets for diagnosis and treatment[J]. J Clin Hepatol, 2019, 35(8): 1874-1877. DOI: 10.3969/j.issn.1001-5256.2019.08.051. 王维钊, 向晓星. Treg/Th17、Th1/Th2平衡在自身免疫性肝炎中的免疫学机制及诊疗新靶点[J]. 临床肝胆病杂志, 2019, 35(8): 1874-1877. DOI: 10.3969/j.issn.1001-5256.2019.08.051.
[22]	CHIKUMA S, KANAMORI M, MISE-OMATA S, et al. Suppressors of cytokine signaling: Potential immune checkpoint molecules for cancer immunotherapy[J]. Cancer Sci, 2017, 108(4): 574-580. DOI: 10.1111/cas.13194.
[23]	TANAKA K, ICHIYAMA K, HASHIMOTO M, et al. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads[J]. J Immunol, 2008, 180(6): 3746-3756. DOI: 10.4049/jimmunol.180.6.3746.
[24]	ZHANG H, JIANG Z, ZHANG L. Dual effect of T helper cell 17 (Th17) and regulatory T cell (Treg) in liver pathological process: From occurrence to end stage of disease[J]. Int Immunopharmacol, 2019, 69: 50-59. DOI: 10.1016/j.intimp.2019.01.005.
[25]	TANG GJ. The role of Th17/Treg cell imbalance in the progression of chronic hepatitis B diseases[D]. Kunming: Kunming Medical University, 2021. DOI: 10.27202/d.cnki.gkmyc.2021.000104. 唐光俊. Th17/Treg细胞失衡在慢性乙型肝炎疾病进展中的作用[D]. 昆明: 昆明医科大学, 2021. DOI: 10.27202/d.cnki.gkmyc.2021.000104.
[26]	TANG GJ, YOU J, LIU HE, et al. Role of T helper 17 cell/regulatory T cell imbalance in the progression of HBV-related liver diseases[J]. J Clin Hepatol, 2021, 37(2): 414-418. DOI: 10.3969/j.issn.1001-5256.2021.02.035. 唐光俊, 游晶, 刘怀鄂, 等. 辅助性T淋巴细胞17/调节性T淋巴细胞比值失衡在HBV相关肝脏疾病进展中的作用[J]. 临床肝胆病杂志, 2021, 37(2): 414-418. DOI: 10.3969/j.issn.1001-5256.2021.02.035.
[27]	QIU J, ZHOU F, LI X, et al. Changes and clinical significance of detailed peripheral lymphocyte subsets in evaluating the immunity for cancer patients[J]. Cancer Manag Res, 2020, 12: 209-219. DOI: 10.2147/CMAR.S221586.
[28]	GRANITO A, MURATORI L, LALANNE C, et al. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4⁺ CD25⁺ Foxp3⁺ regulatory T cells in the immune microenvironment[J]. World J Gastroenterol, 2021, 27(22): 2994-3009. DOI: 10.3748/wjg.v27.i22.2994.
[29]	ZAHRAN AM, NAFADY-HEGO H, MANSOR SG, et al. Increased frequency and FOXP3 expression of human CD8⁺CD25^High+ T lymphocytes and its relation to CD4 regulatory T cells in patients with hepatocellular carcinoma[J]. Hum Immunol, 2019, 80(7): 510-516. DOI: 10.1016/j.humimm.2019.03.014.
[30]	DING W, XU X, QIAN Y, et al. Prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: A meta-analysis[J]. Medicine (Baltimore), 2018, 97(50): e13301. DOI: 10.1097/MD.0000000000013301.
[31]	ZHOU L, WANG J, LYU SC, et al. PD-L1+NEUT, Foxp3+Treg, and NLR as new prognostic marker with low survival benefits value in hepatocellular carcinoma[J]. Technol Cancer Res Treat, 2021, 20: 15330338211045820. DOI: 10.1177/15330338211045820.
[32]	HU ZQ, XIN HY, LUO CB, et al. Associations among the mutational landscape, immune microenvironment, and prognosis in Chinese patients with hepatocellular carcinoma[J]. Cancer Immunol Immunother, 2021, 70(2): 377-389. DOI: 10.1007/s00262-020-02685-7.
[33]	ZHANG L, YANG Z, ZHANG S, et al. Polyploidy spectrum correlates with immunophenotype and shapes hepatocellular carcinoma recurrence following liver transplantation[J]. J Inflamm Res, 2022, 15: 217-233. DOI: 10.2147/JIR.S345681.
[34]	LIU F, LIU W, SANIN DE, et al. Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma[J]. Oncoimmunology, 2020, 9(1): 1746573. DOI: 10.1080/2162402X.2020.1746573.
[35]	BOZWARD AG, WARRICKER F, OO YH, et al. Natural killer cells and regulatory T cells cross talk in hepatocellular carcinoma: Exploring therapeutic options for the next decade[J]. Front Immunol, 2021, 12: 643310. DOI: 10.3389/fimmu.2021.643310.
[36]	ZHOU L, PAN LC, ZHENG YG, et al. Novel strategy of sirolimus plus thymalfasin and huaier granule on tumor recurrence of hepatocellular carcinoma beyond the UCSF criteria following liver transplantation: A single center experience[J]. Oncol Lett, 2018, 16(4): 4407-4417. DOI: 10.3892/ol.2018.9226.
[37]	NALBANT A. IL-17, IL-21, and IL-22 cytokines of T helper 17 cells in cancer[J]. J Interferon Cytokine Res, 2019, 39(1): 56-60. DOI: 10.1089/jir.2018.0057.
[38]	LIANG KH, LAI MW, LIN YH, et al. Plasma interleukin-17 and alpha-fetoprotein combination effectively predicts imminent hepatocellular carcinoma occurrence in liver cirrhotic patients[J]. BMC Gastroenterol, 2021, 21(1): 177. DOI: 10.1186/s12876-021-01761-1.
[39]	ZHOU Y, XU X, DING J, et al. Dynamic changes of T-cell subsets and their relation with tumor recurrence after microwave ablation in patients with hepatocellular carcinoma[J]. J Cancer Res Ther, 2018, 14(1): 40-45. DOI: 10.4103/jcrt.JCRT_775_17.
[40]	HE Y, HWANG S, AHMED YA, et al. Immunopathobiology and therapeutic targets related to cytokines in liver diseases[J]. Cell Mol Immunol, 2021, 18(1): 18-37. DOI: 10.1038/s41423-020-00580-w.
[41]	LEE J, LOZANO-RUIZ B, YANG FM, et al. The multifaceted role of Th1, Th9, and Th17 cells in immune checkpoint inhibition therapy[J]. Front Immunol, 2021, 12: 625667. DOI: 10.3389/fimmu.2021.625667.
[42]	HAN Y, LIU D, LI L. PD-1/PD-L1 pathway: current researches in cancer[J]. Am J Cancer Res, 2020, 10(3): 727-742.
[43]	YARCHOAN M, XING D, LUAN L, et al. Characterization of the immune microenvironment in hepatocellular carcinoma[J]. Clin Cancer Res, 2017, 23(23): 7333-7339. DOI: 10.1158/1078-0432.CCR-17-0950.
[44]	The International Hepato-Pancreato-Biliary Association, Liver Surgery Group of Chinese Medical Association Surgery Branch, Chinese Society of Clinical Oncology Liver Cancer Expert Committee. Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma (2021 version)[J]. Chin J Dig Surg, 2021, 20(7): 740-753. DOI: 10.3760/cma.j.cn115610-20210603-00260. 国际肝胆胰协会中国分会, 中华医学会外科学分会肝脏外科学组, 中国临床肿瘤学会肝癌专家委员会. 基于免疫节点抑制剂的肝细胞癌免疫联合治疗多学科中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(7): 740-753. DOI: 10.3760/cma.j.cn115610-20210603-00260.
[45]	DING J, XU K, SUN S, et al. SOCS1 blocks G1-S transition in hepatocellular carcinoma by reducing the stability of the CyclinD1/CDK4 complex in the nucleus[J]. Aging (Albany NY), 2020, 12(4): 3962-3975. DOI: 10.18632/aging.102865.
[46]	ZHENG X, DONG L, WANG K, et al. MiR-21 Participates in the PD-1/PD-L1 pathway-mediated imbalance of Th17/Treg cells in patients after gastric cancer resection[J]. Ann Surg Oncol, 2019, 26(3): 884-893. DOI: 10.1245/s10434-018-07117-6.
[47]	YANG Z, ZHU H, ZHANG L, et al. DNA methylation of SOCS1/2/3 predicts hepatocellular carcinoma recurrence after liver transplantation[J]. Mol Biol Rep, 2020, 47(3): 1773-1782. DOI: 10.1007/s11033-020-05271-3.
[48]	CABRAL L, REYES P, CROCÈ LS, et al. The Relevance of SOCS1 methylation and epigenetic therapy in diverse cell populations of hepatocellular carcinoma[J]. Diagnostics (Basel), 2021, 11(10): 1825. DOI: 10.3390/diagnostics11101825.